Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Bovax 4-valent and 9-valent HPV Vaccines in Chinese Females
NCT04425291Phase 3Completed
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Start
- May 2020
- Primary completion
- Sep 2021
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle, recombinant human papillomavirus 9-valent vaccine in Cervical Cancer (CC), vulvar cancer, vaginal cancer, genital warts, anal cancer, sponsored by Shanghai Bovax Biotechnology Co., Ltd.. Started May 2020; status: completed.
02
Drugs
quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particlerecombinant human papillomavirus 9-valent vaccine
03
Conditions
Cervical Cancer (CC)vulvar cancervaginal cancergenital wartsanal cancer
Beyond the preview
Go deeper on NCT04425291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04425291.